The interim results of the KEYNOTE-811 trial showed that Pembrolizumab plus trastuzumab and chemotherapy could improve ORR to 74.4% in HER2-positive advanced gastric cancer patients (4). The gene discussed is ERBB2; the disease is gastric cancer.